What is Leerink Partnrs’ Forecast for VIR Q2 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Leerink Partnrs issued their Q2 2025 earnings estimates for Vir Biotechnology in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.95) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.87) EPS.

Several other equities research analysts have also recently weighed in on VIR. JPMorgan Chase & Co. upped their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 10th. Finally, Leerink Partners upped their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Stock Down 2.8 %

Shares of NASDAQ:VIR opened at $10.23 on Tuesday. The business’s 50 day moving average is $8.27 and its 200 day moving average is $8.37. The stock has a market cap of $1.41 billion, a P/E ratio of -2.61 and a beta of 0.51. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $5.54 million. During the same period last year, the business posted ($1.22) earnings per share. The business’s revenue was down 9.8% compared to the same quarter last year.

Insider Buying and Selling at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 14,786 shares of company stock worth $170,172 over the last three months. Corporate insiders own 15.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. grew its holdings in shares of Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares during the last quarter. Public Sector Pension Investment Board lifted its position in Vir Biotechnology by 1.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock worth $1,455,000 after acquiring an additional 2,600 shares during the period. The Manufacturers Life Insurance Company grew its stake in Vir Biotechnology by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock valued at $436,000 after purchasing an additional 3,605 shares during the last quarter. Barclays PLC increased its holdings in shares of Vir Biotechnology by 1.3% in the third quarter. Barclays PLC now owns 550,186 shares of the company’s stock valued at $4,121,000 after purchasing an additional 7,287 shares during the period. Finally, Quest Partners LLC raised its stake in shares of Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after purchasing an additional 7,452 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).